ARVN

Arvinas, Inc. Health Care Pharmaceutical Preparations Russell 3000

$7.86Close $499.1MMarket cap $6.82 – $13.8352-week range Nov 3, 2026Next report · before the open

Highlights

Cautions

Not in an uptrend 0 of 8 trend conditions
Lagging the market RS 17 · weaker than 83% of stocks over 12 months
Far from its high 43% below its 52-week high
Distribution down-day volume 1.5× up-day volume over 50 sessions
Results soon Nov 3, 2026, in 2 days
Financial distress Altman Z″ in the distress zone

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 4, 2026

Off 12-month high 43%

1wk 7.7% price change

1mo 1.6% price change

12-month return 21% market up 11% · its own down 29%

F-score — — Not assessed

Altman Z -1.34 Elevated risk

P/E — price / earnings

PEG — P/E / EPS growth

P/B 1.2× price / book

Earnings yield 33.2% EBIT / enterprise value

Cheaper than 31% of the market · expensive

Revenue growth 0% year on year

EPS growth — latest quarter

Sales growth 1015% latest quarter · +1106 pts

ROE 16% return on equity

Free cash margin 105% -$275.7M FCF

D/E 0.00 long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Piotroski tests

Repair signals

Long-term debt down 33% ($0.0B → $0.0B)

Trade setup

ATR% 4.4% $0.35 a day · 2×ATR $7.16

RS 17 / 99 vs the universe

Trend 0 / 8 trend template

Relative volume 1.5× vs 50-day average

Up/down volume 0.65 50 sessions

Implied move — no option chain · report Nov 3, 2026

Trend template · 0 of 8

Screen verdict

Did not qualify for any screen.

Warning signs

2 flagged

Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
Revenue shrinking Revenue fell 0.3% over the year, from $263.4M to $262.6M.

Last reported Aug 4, 2026

Results reaction Aug 4, 2026+3% vs market2 sessions after results

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $262.6M -0.3% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$81.0M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$275.7M

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Net -31%
Free cash -105%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $142.5M net cash

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 63.50m +30.9% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$21.8M	$46.7M	$131.4M	$78.5M	$263.4M	$262.6M
Operating income	-$120.8M	-$188.4M	-$263.2M	-$401.5M	-$250.2M	-$118.5M
Net income	-$119.3M	-$191.0M	-$283.0M	-$367.0M	-$199.0M	-$81.0M
Net margin	-547%	-409%	-215%	-468%	-76%	-31%
Earnings per share	-$3.02	-$3.82	-$5.32	-$6.61	-$2.77	-$1.14
Free cash flow	-$96.1M	$554.7M	-$280.3M	-$350.7M	-$261.1M	-$275.7M
Free cash margin	-441%	1188%	-213%	-447%	-99%	-105%
Cash	$588.4M	$108.3M	$81.3M	$311.7M	$100.5M	$142.9M
Long-term debt	$2.0M	$1.0M	$1.0M	$800,000	$600,000	$400,000
Shareholders' equity	$642.2M	$781.7M	$564.9M	$660.0M	$561.7M	$433.9M
Shares outstanding	48.50m	53m	53.20m	68m	68.80m	63.50m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 4, 2026	Quarterly ↗	Jun 30, 2026	35d
May 11, 2026	Quarterly ↗	Mar 31, 2026	41d
Feb 24, 2026	Annual ↗	Dec 31, 2025	55d
Nov 5, 2025	Quarterly ↗	Sep 30, 2025	36d
Aug 6, 2025	Quarterly ↗	Jun 30, 2025	37d
May 1, 2025	Quarterly ↗	Mar 31, 2025	31d
Feb 11, 2025	Annual ↗	Dec 31, 2024	42d
Oct 30, 2024	Quarterly ↗	Sep 30, 2024	30d
Jul 30, 2024	Quarterly ↗	Jun 30, 2024	30d
May 7, 2024	Quarterly ↗	Mar 31, 2024	37d
Feb 27, 2024	Annual ↗	Dec 31, 2023	58d
Nov 7, 2023	Quarterly ↗	Sep 30, 2023	38d

Current reports

Filed	Disclosed
Aug 4, 2026	Results ↗
Jun 25, 2026	Shareholder vote ↗
Jun 22, 2026	Director or officer change ↗
Jun 16, 2026	Other events ↗
Jun 2, 2026	Regulation FD · Other events ↗
May 12, 2026	Results ↗
May 12, 2026	Material agreement · Regulation FD ↗
May 1, 2026	Regulation FD · Other events ↗
Mar 18, 2026	Regulation FD · Other events ↗
Feb 24, 2026	Results ↗
Feb 12, 2026	Director or officer change ↗
Dec 8, 2025	Regulation FD · Other events ↗